MiMedx Group (MDXG) Stock Price Down 3.1%

MiMedx Group Inc (NASDAQ:MDXG) was down 3.1% during trading on Monday . The company traded as low as $3.96 and last traded at $4.28. Approximately 62,594 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 5,054,293 shares. The stock had previously closed at $4.15.

A number of equities research analysts have recently commented on MDXG shares. ValuEngine cut MiMedx Group from a “sell” rating to a “strong sell” rating in a research note on Wednesday, May 2nd. BidaskClub cut MiMedx Group from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 16th. Two analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $16.00.

The firm has a market cap of $460.80 million, a PE ratio of 19.76 and a beta of 1.56.

Several large investors have recently made changes to their positions in MDXG. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in shares of MiMedx Group during the first quarter valued at $139,000. Hartford Investment Management Co. bought a new position in MiMedx Group in the second quarter valued at about $153,000. Xact Kapitalforvaltning AB bought a new position in MiMedx Group in the fourth quarter valued at about $182,000. OppenheimerFunds Inc. lifted its holdings in MiMedx Group by 67.6% in the first quarter. OppenheimerFunds Inc. now owns 26,458 shares of the medical equipment provider’s stock valued at $184,000 after acquiring an additional 10,676 shares during the period. Finally, Financial Advocates Investment Management bought a new position in MiMedx Group in the first quarter valued at about $211,000. 75.87% of the stock is currently owned by hedge funds and other institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc, a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts.

Recommended Story: Price to Earnings Ratio (PE)

Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply